Published in Biol Blood Marrow Transplant on July 20, 2011
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A (2013) 1.02
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer (2012) 0.91
Circulating tumor cells in breast cancer. J Carcinog (2014) 0.83
The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol (2012) 0.80
High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? Biol Blood Marrow Transplant (2011) 0.76
Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiol Spectr (2016) 0.75
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Is cancer a disease of self-seeding? Nat Med (2006) 3.19
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol (1984) 2.52
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant (2006) 1.66
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet (1993) 1.53
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant (2000) 1.48
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood (1994) 1.45
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer (1999) 1.19
Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer (2011) 1.15
Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol (1996) 1.09
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant (2001) 1.04
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol (2005) 0.98
High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer (2005) 0.95
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol (1986) 0.95
High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol (2009) 0.93
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant (2006) 0.91
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol (2006) 0.89
Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant (2007) 0.89
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood (1998) 0.88
Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol (1998) 0.85
Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol (1996) 0.82
Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant (2002) 0.82
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant (1997) 0.82
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol (1995) 0.81
A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol (2007) 0.81
Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol (1994) 0.81
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant (2002) 0.81
Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother (1996) 0.78
Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Med Oncol (1999) 0.78
Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. Cytotherapy (2001) 0.78
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature (2003) 12.81
Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature (2003) 12.54
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature (2005) 11.23
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
Little evidence for developmental plasticity of adult hematopoietic stem cells. Science (2002) 9.63
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature (2004) 8.36
Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol (2002) 7.78
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature (2007) 7.72
Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol (2002) 7.03
Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A (2005) 6.32
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
Stems cells and the pathways to aging and cancer. Cell (2008) 5.99
Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med (2005) 5.68
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell (2007) 5.28
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR. Proc Natl Acad Sci U S A (2006) 5.21
Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell (2004) 5.20
Plasticity of adult stem cells. Cell (2004) 5.13
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev (2003) 4.71
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A (2003) 4.41
Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell (2002) 4.37
Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol (2006) 4.32
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A (2003) 4.09
Protective conditioning for acute graft-versus-host disease. N Engl J Med (2005) 4.07
Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med (2012) 4.05
Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med (2008) 4.04
Coronary arteries form by developmental reprogramming of venous cells. Nature (2010) 3.95
Cancer stem cells in solid tumors. Curr Opin Biotechnol (2007) 3.91
Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature (2008) 3.87
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat Med (2009) 3.82
Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat Biotechnol (2011) 3.81
Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med (2003) 3.74
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell (2007) 3.59
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A (2010) 3.41
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A (2014) 3.39
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 3.33
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med (2004) 3.17
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood (2005) 3.13
Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet (2005) 3.11
An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol (2011) 3.05
Germ-layer and lineage-restricted stem/progenitors regenerate the mouse digit tip. Nature (2011) 3.03
Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol (2007) 3.00
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol (2008) 2.99
Isolation and characterization of a protochordate histocompatibility locus. Nature (2005) 2.96
Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A (2011) 2.96
Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med (2002) 2.96
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2004) 2.95
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A (2006) 2.94
Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med (2005) 2.92
Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One (2008) 2.85
Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A (2006) 2.83
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood (2002) 2.79
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood (2012) 2.77
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A (2009) 2.76
Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science (2007) 2.69
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood (2011) 2.69
microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med (2010) 2.68
Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell (2008) 2.67
Ethics. The ISSCR guidelines for human embryonic stem cell research. Science (2007) 2.62
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature (2016) 2.53
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev (2009) 2.46
Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands. Dev Cell (2006) 2.45
Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med (2010) 2.38
Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 2.37
Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell (2011) 2.35
New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell (2006) 2.34
MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell (2003) 2.33
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood (2003) 2.33